U.S. judge rules Actavis must continue to sell Alzheimer's drug

(Reuters) - A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug. In September, New York Attorney General Eric Schneiderman sued Actavis and its New York-based subsidiary, Forest Laboratories, to stop the company from discontinuing sales of the drug, which is due to lose patent protection next year. ...



via Health News Headlines - Yahoo News http://ift.tt/1yEQZzu